Prostate cancer is the leading form of cancer in men. Although it mainly affects men over 60, it is not rare in younger men. The Eugène Marquis Centre has long partnered with the urology team at Rennes University Teaching Hospital to treat patients with prostate cancer.
Most prostate cancers develop slowly: the tumour remains confined to the prostate, with a limited impact on health. These cancers can sometimes be aggressive, however, and may spread to other organs. They are diagnosed by anatomopathological examination (examination under a microscope of a sample of prostate tissue taken during a biopsy performed by the urologist).
In collaboration with the urology team at Rennes University Teaching Hospital, the Eugène Marquis Centre is fully equipped to treat all forms of prostate cancer, both localised and non-localised.Treatment may be provided as part of a clinical trial.
Doctors from both establishments attend weekly multidisciplinary team meetings on urological oncology, during which they make joint treatment decisions and design personalised care programmes for each patient.
To treat localised prostate cancer, the Eugène Marquis Centre deploys a number of innovative techniques in the fields of external radiotherapy (intensity modulation, dynamic arc therapy, image-guided therapy) and brachytherapy.
The urology team at Rennes University Teaching Hospital confirm diagnoses using prostate MRI and biopsy, implement proactive monitoring procedures, perform (robotic) surgery and provide Ablatherm treatment.
Current guidance for localised cancers with good prognoses is to reduce the aggressiveness of treatment by using minimally invasive techniques, or even just proactive monitoring.
If treatment is required, it is rarely urgent, given how slowly the disease develops. Patients sometimes have a choice of treatments.
To treat more advanced forms of prostate cancer, doctors at the Eugène Marquis Centre offer a range of therapies, including hormone therapy, chemotherapy, targeted therapies, external radiotherapy and supportive care.Treatment is often carried out as part of clinical trials.
If the patient’s PSA level remains high even after local therapy, tracers such as choline can be used to detect the early stages of reoccurrence in the pelvic ganglion or the appearance of a separate metastatic tumour that could be treated with a new round of local therapy, such as stereotactic radiotherapy.
Some types of prostate cancer are associated with hereditary predisposition. In such cases, the patient may be offered genetic counselling. This allows a personalised follow-up plan to be designed for predisposed individuals.
The aim of genetic counselling is to identify whether there is a higher risk of cancer within the family and whether it is caused by a genetic mutation. Once the results have been received, the consultant can provide practical prevention and testing guidance and a personalised follow-up plan.